
What smart money is saying about Sartorius
1 fund in our archive has pitched Sartorius — most recently Artisan Global Discovery Strategy in June 2025.
Sartorius AG is a global supplier of advanced bioprocess and laboratory solutions, offering a comprehensive portfolio of products and services essential for life science research and biopharmaceutical manufacturing. The company's offerings include sophisticated biosensors and detection systems, live-cell analysis platforms, and a wide array of cell culture media and reagents. Sartorius also manufactures various bioreactors, ranging from benchtop to large-scale single-use and stainless steel systems, along with their associated software applications. Its extensive filtration product line encompasses membranes, specialized filters, and diverse devices for ultrafiltration, sterile filtration, and sample preparation. Furthermore, Sartorius provides process chromatography and fluid management solutions, industrial microbiology systems, water purification units, and essential lab equipment such as weighing, pipetting, and centrifugation systems. Beyond products, the company delivers critical services including bioprocess development, protein expression, and validation. Serving sectors like life science research, biopharmaceutical manufacturing, and quality control, Sartorius was established in 1870 and is headquartered in Göttingen, Germany.
Get an email when a fund writes about it
Fund coverage · 1 thesis
- Artisan Global Discovery StrategyJune 2025
Sartorius is well-positioned to benefit from the shift towards biologic drugs, with recent strong earnings and accelerating orders suggesting a potential recovery from prior volatility.
Read the full thesis
Read every full thesis on Sartorius
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→